Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Salvatore Fiorenza

Showing results (1-10 of 33) with videos related to

Pageof 4
Sort By:
Blood Advances|October 31, 2025
ctDNA MRD after CAR-TSalvatore Fiorenza, Mark R Dowling
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|April 7, 2021
CAR-T Cell Therapy for Acute Myeloid Leukemia: Preclinical Rationale, Current Clinical Progress, and Barriers to SuccessSalvatore Fiorenza, Cameron J Turtle
Blood|December 12, 2024
High-dimensional data bridges for CARsSalvatore Fiorenza, Cameron J Turtle
Immunometabolism|February 8, 2021
Associations between the Gut Microbiota, Immune Reconstitution, and Outcomes of Allogeneic Hematopoietic Stem Cell TransplantationSalvatore Fiorenza, Cameron J Turtle
International Journal of Molecular Sciences|September 14, 2024
Safety and Efficacy of Bispecific Antibodies in Adults with Large B-Cell Lymphomas: A Systematic Review of Clinical Trial DataElena Bayly-McCredie, Maxine Treisman, Salvatore Fiorenza
Microorganisms|October 29, 2025
Associations Between the Gut Microbiome and Outcomes in Autologous Stem Cell Transplantation: A Systematic ReviewEma Pitts, Brian Grainger, Dean McKenzie, et al.
Neuroscience Letters|August 11, 2020
Eye blink rate increases as a function of cognitive load during an auditory oddball paradigmAlfonso Magliacano, Salvatore Fiorenza, Anna Estraneo, et al.
Nature Reviews. Clinical Oncology|February 18, 2025
Outcome correlates of approved CD19-targeted CAR T cells for large B cell lymphomaTamara J Bock, Chanukya K Colonne, Salvatore Fiorenza, et al.
Expert Opinion on Biological Therapy|March 19, 2025
An evaluation of odronextamab for the treatment of multiple subtypes of relapsed/refractory B-cell non-Hodgkin lymphomaElena Bayly-McCredie, Henry Miles Prince, Costas Kleanthes Yannakou, et al.
Frontiers in Medicine|March 30, 2026
Editorial: Novel therapies and unexpected challenges: overcoming immune-mediated toxicities in modern oncologyIgor Age Kos, Salvatore Fiorenza, Michel Michels de Oliveira, et al.
Pageof 4

Showing results (1-10 of 33) with videos related to

Sort By:
Pageof 4
Blood Advances|October 31, 2025
ctDNA MRD after CAR-TSalvatore Fiorenza, Mark R Dowling
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|April 7, 2021
CAR-T Cell Therapy for Acute Myeloid Leukemia: Preclinical Rationale, Current Clinical Progress, and Barriers to SuccessSalvatore Fiorenza, Cameron J Turtle
Blood|December 12, 2024
High-dimensional data bridges for CARsSalvatore Fiorenza, Cameron J Turtle
Immunometabolism|February 8, 2021
Associations between the Gut Microbiota, Immune Reconstitution, and Outcomes of Allogeneic Hematopoietic Stem Cell TransplantationSalvatore Fiorenza, Cameron J Turtle
International Journal of Molecular Sciences|September 14, 2024
Safety and Efficacy of Bispecific Antibodies in Adults with Large B-Cell Lymphomas: A Systematic Review of Clinical Trial DataElena Bayly-McCredie, Maxine Treisman, Salvatore Fiorenza
Microorganisms|October 29, 2025
Associations Between the Gut Microbiome and Outcomes in Autologous Stem Cell Transplantation: A Systematic ReviewEma Pitts, Brian Grainger, Dean McKenzie, et al.
Neuroscience Letters|August 11, 2020
Eye blink rate increases as a function of cognitive load during an auditory oddball paradigmAlfonso Magliacano, Salvatore Fiorenza, Anna Estraneo, et al.
Nature Reviews. Clinical Oncology|February 18, 2025
Outcome correlates of approved CD19-targeted CAR T cells for large B cell lymphomaTamara J Bock, Chanukya K Colonne, Salvatore Fiorenza, et al.
Expert Opinion on Biological Therapy|March 19, 2025
An evaluation of odronextamab for the treatment of multiple subtypes of relapsed/refractory B-cell non-Hodgkin lymphomaElena Bayly-McCredie, Henry Miles Prince, Costas Kleanthes Yannakou, et al.
Frontiers in Medicine|March 30, 2026
Editorial: Novel therapies and unexpected challenges: overcoming immune-mediated toxicities in modern oncologyIgor Age Kos, Salvatore Fiorenza, Michel Michels de Oliveira, et al.
Pageof 4